Skip to main content

Table 3 Quality summary: authors’ assessment of risk of bias in randomised controlled trials included in meta-analysis

From: Fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis

Author Random sequence generation Allocation concealment Blinding of participants, personnel and outcome assessors Incomplete outcome data Selective outcome reporting Commercial involvement Other sources of bias Overall assessment
O’Hara et al. [19] Low risk Low risk Low risk Low risk Low risk Low risk Low risk Low risk
Ranucci et al. [17] Low risk Low risk Low risk Low risk Low risk Low risk High riska High risk
Barr et al. [15] Unclear Low risk Low risk Low risk Low risk Low risk Low riska High risk
Cogliati et al. [16] Low risk Low risk Low risk Low risk Low risk Unclear High riska High risk
Biancofiore et al. [18] Low risk Low risk Low risk Low risk Low risk Low risk High riska High risk
Halpenny et al. [5] Unclear Unclear Low risk Low risk Low risk Unclear High riskb High risk
  1. Risk of bias was judged by the authors to be high, unclear or low according to the Cochrane Collaboration’s risk of bias assessment tool
  2. aHigh risk due to potential imbalance in number of patients with pre-existing chronic kidney disease
  3. bHigh risk because the definition of AKI was not provided